Definium Therapeutics, Inc. (DFTX)
$41.13-$2.69 (-6.14%) Today
Latest DFTX Insider Trades
Mark Sullivan - OfficerOpen-market sale
Mark Sullivan - OfficerMark Sullivan - OfficerDefinium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 58,131 | $2.62M |
| Grant or award | 22 | 1,462,445 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
42 Form 4 filings on record, the earliest from Dec 5, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Robert Barrow - Officer | Grant or award | Common Shares | 375,000 | $0.00 | - | |
| Daniel Karlin - Officer | Grant or award | Common Shares | 100,000 | $0.00 | - | |
| Mark Sullivan - Officer | Grant or award | Common Shares | 62,500 | $0.00 | - | |
| Matthew T. Wiley - Officer | Grant or award | Common Shares | 62,500 | $0.00 | - | |
| Brandi Roberts - Officer | Grant or award | Common Shares | 62,500 | $0.00 | - | |
| Mark Sullivan - Officer | Open-market sale | Common Shares | 13,008 | $45.03 | $586K | |
| Brandi Roberts - Officer | Open-market sale | Common Shares | 3,013 | $45.03 | $136K | |
| Robert Barrow - Officer | Open-market sale | Common Shares | 29,208 | $45.03 | $1.32M | |
| Daniel Karlin - Officer | Open-market sale | Common Shares | 10,035 | $45.03 | $452K | |
| Matthew T. Wiley - Officer | Open-market sale | Common Shares | 2,867 | $45.03 | $129K | |
| Matthew T. Wiley - Officer | Grant or award | Common Shares | 62,500 | $0.00 | - | |
| Robert Barrow - Officer | Grant or award | Common Shares | 375,000 | $0.00 | - | |
| Mark Sullivan - Officer | Grant or award | Common Shares | 62,500 | $0.00 | - | |
| Brandi Roberts - Officer | Grant or award | Common Shares | 62,500 | $0.00 | - | |
| Daniel Karlin - Officer | Grant or award | Common Shares | 100,000 | $0.00 | - | |
 Roger Crystal | Grant or award | Common Shares | 4,666 | $0.00 | - | |
| Roger Crystal | Grant or award | Stock Option (Right to Buy) | 19,188 | $0.00 | - | |
| David W. Gryska | Grant or award | Common Shares | 4,666 | $0.00 | - | |
| David W. Gryska | Grant or award | Stock Option (Right to Buy) | 19,188 | $0.00 | - | |
 Carol A. Vallone | Grant or award | Stock Option (Right to Buy) | 19,188 | $0.00 | - | |
| Carol A. Vallone | Grant or award | Common Shares | 4,666 | $0.00 | - | |
| Andreas Krebs | Grant or award | Common Shares | 4,666 | $0.00 | - | |
| Andreas Krebs | Grant or award | Stock Option (Right to Buy) | 19,188 | $0.00 | - | |
 Roger Adsett | Grant or award | Stock Option (Right to Buy) | 14,620 | $0.00 | - | |
| Roger Adsett | Grant or award | Common Shares | 3,555 | $0.00 | - | |
 Suzanne Louise Bruhn | Grant or award | Common Shares | 4,666 | $0.00 | - | |
| Suzanne Louise Bruhn | Grant or award | Stock Option (Right to Buy) | 19,188 | $0.00 | - | |
| Daniel Karlin - Officer | Open-market sale | Common Shares | 8,018 | $18.47 | $148K | |
| Mark Sullivan - Officer | Open-market sale | Common Shares | 10,702 | $18.47 | $198K | |
| Robert Barrow - Officer | Open-market sale | Common Shares | 24,431 | $18.47 | $451K | |
| Matthew T. Wiley - Officer | Grant or award | Common Shares | 115,000 | $0.00 | - | |
| Brandi Roberts - Officer | Grant or award | Common Shares | 150,000 | $0.00 | - | |
| Mark Sullivan - Officer | Grant or award | Common Shares | 125,000 | $0.00 | - | |
| Daniel Karlin - Officer | Grant or award | Common Shares | 150,000 | $0.00 | - | |
| Robert Barrow - Officer | Grant or award | Common Shares | 320,000 | $0.00 | - | |
| Roger Adsett | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Definium Therapeutics, Inc. (DFTX) had 21 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for DFTX runs to 42 Form 4 filings, the earliest from 2024-12-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of DFTX were filed in the last 90 days. 1 purchase is on record for this company.
5 insider sales of DFTX were filed in the last 90 days, totaling $2.62M.
This page tracks DFTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DFTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
